Development and Evaluation of a Bispecific Single-Chain Antibody Targeting PSMA and CD3 to Enhance T-Cell-Mediated Lysis

< .001). Enhanced T-cell activation, infiltration, and IFN-γ release were observed, accompanied by increased tumor necrosis and apoptosis. The PSMA-CD3 bispecific antibody effectively redirected T-cell cytotoxicity against prostate cancer cells, resulting in robust antitumor activity and survival benefit. These findings support further translational development of bispecific immunotherapies for advanced prostate cancer.